Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing

SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) — Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing. “Dr. Gerner’s extensive experience in biotechnology product development and manufacturing is […]